| Market Cap | $1.04B-12.9% |
| Revenue (ttm) | $217.86M |
| Net Income | -$110.75M |
| EPS | -$1.20 |
| Shares Out | 111.50M |
| PE Ratio | n/a |
| Forward PE | -3.74 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 621,416 |
| Open | $9.82 |
| Previous Close | $9.93 |
| Day's Range | $9.28 - $9.84 |
| 52-Week Range | $9.28 - $17.50 |
| Beta | 0.60 |
| Analysts | Strong Buy |
| Price Target | $18.00(+92.31%) |
| Earnings Date | n/a |
About FRNM
Freenome, Inc., a biotechnology company, develops blood-based screening tests to detect cancer in the United States. The company offers an early cancer detection platform that integrates multiomics, artificial intelligence, and machine learning to uncover complex biological signals associated with cancer. It develops SimpleScreen CRC, a blood-based test, including a test for colorectal cancer screening, as well as tests for multi-cancer and multi-disease detection, such as lung, breast, cervical, liver, pancreatic, and esophageal cancers. The company was founded in 2014 and is headquartered in Brisbane, California.
$FRNM stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in FRNM holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by FRNM's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
FRNM Estimated quarterly lobbying spending
Source: U.S. Senate LDA
FRNM Revenue by Segment or Geography
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New FRNM patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to FRNM from public contracts
Source: USAspending.gov
Bull Case vs Bear Case
AI-generated from FRNM’s recent data — informational, not investment advice
What’s Behind the Score
News check: Q3 2026 results show swing to profitability and rising revenue, offset by participation in analyst conference without major announcements.
